Skip to main content

Table 2 ACE genotype and allele distributions among controls and migraine patients in a Norwegian population

From: Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients

  

Genotypes

Alleles

 

N

DD(%)

ID(%)

II(%)

D(%)

I(%)

Controls

403

92 (26.6)

204 (50.6)

107 (22.8)

388 (48.1)

418 (51.9)

Migraine

347

78 (22.5)

186 (53.6)

83 (23.9)

342 (49.3)

352 (50.7)

MwA subgroup

155

34 (21.9)

87 (56.1)

34 (21.9)

155 (50.0)

155 (50.0)

MoA subgroup

187

43 (23.0)

96 (51.3)

48 (25.7)

182 (48.7)

192 (51.3)

Lisinopril responders

12

2 (16.7)

6 (50.0)

4 (33.3)

10 (41.7)

14 (58.3)

Lisinopril non-responders

37

10 (27.0)

16 (43.2)

11 (29.7)

36 (48.6)

38 (51.4)

Candesartan responders*

18

7 (38.9)

9 (50.0)

2 (11.1)

23 (63.9)

13 (36.1)

Candesartan non-responders*

38

8 (21.1)

18 (47.4)

12 (31.6)

34 (44.7)

42 (55.3)

Responders combined

30

9 (30.0)

15 (50.0)

6 (20.0)

33 (55.0)

27 (45.0)

Non-responders combined

75

18 (24.0)

34 (45.3)

23 (30.7)

70 (46.7)

80 (53.3)

  1. * Response data available in 56 of 59 genotyped
  2. Allele and genotype frequency distributions are not significantly different for any diagnostic groups (migraine, MwA, MoA) vs controls, or for responders vs non-responders (p > 0.05).